Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    New social media icons for Twitter and LinkedIn were added to the header, providing quick access to AstraZeneca's social channels from the Press Releases page.
    Difference
    2%
    Check dated 2026-05-10T09:21:54.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Five new press releases were added to the list: Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (30 April 2026); Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer (30 April 2026); Q1 2026 results (29 April 2026); Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older (28 April 2026); and Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus (27 April 2026). Additionally, older press releases were removed from the archive.
    Difference
    5%
    Check dated 2026-05-03T03:18:00.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    New recent press release entries were added to the press releases list, including items dated 21 April 2026 and 20 April 2026. Two earlier press release items were removed, including one dated 10 February 2026 and another dated 03 February 2026.
    Difference
    5%
    Check dated 2026-04-25T18:51:09.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    Added a new press release entry for 10 April 2026 about Alexion data at the 2026 AAN Annual Meeting. Removed the 03 February 2026 update on Saphnelo subcutaneous administration in systemic lupus erythematosus.
    Difference
    0.9%
    Check dated 2026-04-11T10:44:51.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    Added two press releases: EMERALD-3 trial results for Imfinzi plus Imjudo with lenvatinib and TACE (02 April 2026) and Efzimfotase alfa Phase III results in hypophosphatasia (31 March 2026). Deleted two items: Imfinzi perioperative regimen recommended for EU approval by CHMP (02 February 2026) and AstraZeneca begins trading on the New York Stock Exchange.
    Difference
    5%
    Check dated 2026-04-04T06:14:52.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    Added a new press release about Tozorakimab meeting primary endpoints in COPD Phase III trials (27 March 2026); removed the January 30, 2026 CSPC collaboration press release from the list.
    Difference
    0.9%
    Check dated 2026-03-28T03:42:31.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.